The finance chief's chair is the busiest seat in the C-suite

Planned handovers, long tails

Concentrix disclosed the most orderly handover in the batch. Chinnu Susan Varghese will succeed Andre Valentine as chief financial officer, with the appointment effective December 1, 2026, and Varghese joining the company on November 9, 2026. Valentine will continue in the role in the near term and remain through the second quarter of fiscal 2027 to facilitate the transition, which gives the company roughly two quarters of overlap between outgoing and incoming finance chiefs. m:…8998

Pfizer's move was a confirmation rather than a search. Cecile Guegan was appointed chief financial officer and executive vice president on a permanent basis effective November 1, 2026. She has been with the company since 2009 and served as interim CFO starting in August 2026, so the filing stabilizes a role that had already been hers in practice for months. m:…9440

Willis Towers Watson disclosed a handover with the longest runway. Steven Alcock will become principal accounting officer and controller effective April 1, 2027, succeeding Joseph Kurpis, who had previously notified the company of his intent to retire. Alcock currently serves as head of finance, international, and as chief financial officer of the subsidiary Willis Limited, so the successor is an internal promotion announced five months ahead of the start date. m:…0497

Interim seats and abrupt exits

Erie Indemnity's change was faster and less settled. The company announced the accelerated retirement of president and CEO Timothy G. NeCastro effective November 2, 2026, and appointed Brian W. Bolash, previously executive vice president, secretary and general counsel, as interim president and CEO effective November 3, 2026. The board is searching for a permanent successor, which means the company's top job is explicitly temporary for now. m:…6140

BGC Group disclosed a different kind of transition: JP Aubin will step down as co-CEO, CEO of EMEA and co-global head of financial services brokerage effective December 31, 2026, and become vice chairman. John J. Abularrage and Sean A. Windeatt will remain as co-CEOs, overseeing all company regions and businesses. The move removes a co-CEO without creating a vacancy, since two co-CEOs remain. m:…0695

Anavex Life Sciences appointed Terrie Kellmeyer as permanent CEO and president effective November 1, 2026, after her tenure as interim CEO, and also appointed her to a board reduced in size from six to five members, with a review of her employment agreement and compensation by an independent consultant planned in the near term. Enovix, by contrast, disclosed the departure of its chief financial officer and corporate secretary Arthi Chakravarthy effective October 30, 2026, without immediately naming a successor. The contrast between a planned interim-to-permanent path and an exit with no named replacement is the governance detail that matters most in this batch. m:…5185 m:…5694

What the pay packages say

The pay disclosures filed alongside the moves show what boards are spending to secure finance leadership. ACM Research appointed Yue Ma as chief financial officer effective October 1, 2026, with an annual base salary of $375,000, a target annual bonus of $100,000, and a package including 100,000 stock options and 13,470 restricted stock units subject to vesting schedules and board approval. Ma previously worked at ASML Holding, so the package is the price of importing experience from a larger semiconductor company. m:…0736

Financial Corporation disclosed a new employment agreement with Sean A. Gray as president and CEO, effective September 21, 2026, providing a $1,000,000 base salary, a 75 percent target annual bonus, annual equity awards valued at 105 percent of base salary, a one-time $275,000 restricted stock award, and severance provisions triggered by termination without cause or a change in control. The structure ties most of the value to equity and to staying through a change in control, which is a retention design as much as a pay design. m:…3959

Guardant Health's board approved performance-based restricted stock unit awards for co-CEOs Helmy Eltoukhy and AmirAli Talasaz, granting each 465,413 target units with vesting contingent on relative total shareholder return against the S&P 500 over three-year and five-year periods, plus post-vesting holding requirements and provisions for termination and change-in-control scenarios. The filing frames the awards as aligning executive incentives with long-term shareholder value, and the relative-return test means the units pay out only if the company beats the market, not merely if its shares rise. m:…3637

How to read the batch

Read together, the filings sort into two groups. In one, boards had a successor ready or an interim already in place: Concentrix with its two-quarter overlap, Pfizer confirming its interim, Willis Towers Watson promoting from within, Anavex converting its interim CEO. In the other, the seat is open or newly temporary: Enovix with no named successor, Erie with an interim CEO and a search under way. The first group is a story about continuity planning; the second is a story about exposure, since a company without a named finance chief or permanent CEO is negotiating its next chapter with a gap at the top. m:…8998 m:…5694

The pay packages cut across both groups in the same direction: longer vesting, relative-performance tests and change-in-control provisions all make it expensive for an executive to leave and valuable to stay through turbulence. For executives weighing a move, the signal is that boards are paying for retention as much as for performance. For investors, the signal is that the cost of leadership stability is rising, and it is being disclosed in the same filings as the departures themselves. m:…3637 m:…3959